TABLE 1.

Characteristics of patients before initiation of ribavirin therapy

Characteristic	Value for group with 1634R variant:		P value
	Present (n = 23)	Absent (n = 40)
No. of males/females	16/7	32/8	0.37
Median (range) age, yr	48.5 (20–73)	48 (7–83)	0.54
No. with transplantation type:			0.38
Kidney	17	28
Liver	3	7
Heart	3	2
Lung	0	3
No. with immunosuppressive regimen at start of ribavirin:
Tacrolimus/cyclosporine	19/0	29/2	0.54
Mycophenolic acid	18	30	1
mTORa inhibitors	3	6	1
Steroids	19	30	0.54
Median (range) time between diagnosis and ribavirin therapy, mo	13 (1–54)	4 (0.5–47)	0.29
Median (range) ribavirin dose, mg/kg/day	9.8 (4.3–13.3)	8.1 (0.01–16.3)	0.21
Median (range) ribavirin duration, mo	3 (3–18)	3 (3–6)	0.65
No. (%) with HEV genotype:			0.07
3c	3 (8.6)	14 (35)
3e	4 (17.4)	1 (2.5)
3f	13 (56.5)	21 (52.5)
Undetermined	3 (8.6)	4 (10)
Median (range) plasma HEV RNA concn, log copies/ml	6.2 (4.4–7.5)	5.8 (3.5–7.4)	0.05

^amTOR, mammalian target of rapamycin.